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While TOFA (acetyl CoA carboxylase inhibitor) and C75 (fatty acid synthase inhibitor) prevent lipid accumulation by inhibiting
fatty acid synthesis, themechanism of action is not simply accounted for by inhibition of the enzymes alone. Liver fatty acid binding
protein (L-FABP), a mediator of long chain fatty acid signaling to peroxisome proliferator-activated receptor-𝛼 (PPAR𝛼) in the
nucleus, was found to bind TOFA and its activated CoA thioester, TOFyl-CoA, with high affinity while binding C75 and C75-
CoA with lower affinity. Binding of TOFA and C75-CoA significantly altered L-FABP secondary structure. High (20mM) but not
physiological (6mM) glucose conferred on both TOFA and C75 the ability to induce PPAR𝛼 transcription of the fatty acid 𝛽-
oxidative enzymes CPT1A, CPT2, and ACOX1 in cultured primary hepatocytes fromwild-type (WT)mice. However, L-FABP gene
ablation abolished the effects of TOFA and C75 in the context of high glucose. These effects were not associated with an increased
cellular level of unesterified fatty acids but rather by increased intracellular glucose. These findings suggested that L-FABP may
function as an intracellular fatty acid synthesis inhibitor binding protein facilitating TOFA and C75-mediated induction of PPAR𝛼
in the context of high glucose at levels similar to those in uncontrolled diabetes.
1. Introduction
Obesity and overweight are worldwide health problems,
affecting >50% of the US population and exceeding tobacco
as the major cause of preventable mortality in the USA [1–3].
Obesity is associated with the development of type 2 diabetes
(NIDDM), cardiovascular disease, nonalcoholic fatty liver
disease (NAFLD), and increased mortality [2, 4–7]. Conse-
quently, increasing effort in therapeutics has focused on the
development of drugs such as TOFA, C75, and cerulenin that
target the fatty acid metabolic pathway to inhibit synthesis.
C75 is a competitive irreversible, slow-binding inhibitor of
fatty acid synthase (FASN), cerulenin is suicide inhibitor of
FASN, and TOFA is an allosteric inhibitor of acetyl CoA
carboxylase (ACC) [8–11]. While these agents lower whole
body and adipose tissue weight, their mechanism(s) of action
is not simply accounted for by inhibition of the FASN and
ACC enzymes alone.
Increased malonyl-CoA, for example, inhibits carnitine
palmitoyl transferase 1A (CPT1A, the rate limiting enzyme in
mitochondrial fatty acid 𝛽-oxidation) [8, 11]. Since the ACC
inhibitor TOFA decreases malonyl CoA while the two FASN
inhibitors (C75, cerulenin) increase malonyl-CoA, it was
anticipated that TOFA would enhance while C75 and ceru-
lenin would inhibit CPT1A and fatty acid 𝛽-oxidation [8, 11,
12]. Despite these opposite expectations, however, bothTOFA
and C75 enhanced CPT1A activity and fatty acid 𝛽-oxidation
while cerulenin exhibited a biphasic effect characterized by
short-term (1 h) inhibition followed by longer term (3–5 h)
stimulation fatty acid 𝛽-oxidation [8, 11–13]. Similar opposite
effects of closely related fatty acid synthesis inhibitors on
fatty acid oxidation are not uncommon [14]. While some
paradoxical effects of these agents have been attributed in
part to actions in the central nervous system (e.g., reduced
food intake), this alone also does not completely explain
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Figure 1: Structural comparisons of the fatty acid synthesis
inhibitors TOFA and C75 with natural and fluorescent fatty acids.
the effects of TOFA (does not inhibit feeding), C75 (inhibits
feeding), and cerulenin (activity not highly correlated with
food intake) on increasing CPT1A and fatty acid 𝛽-oxidation
[1–3, 8, 10, 13].
Recent studies fromour laboratory and other laboratories
have established a signaling pathway, whereby the liver fatty
acid binding protein (L-FABP) facilitates uptake and intra-
cellular targeting of poorly soluble fatty acids and fibrates
to PPAR𝛼 in the nucleus (review in [16–18]). PPAR𝛼 binds
and is activated by LCFA and LCFA-CoA and a variety
of lipid lowering drugs (fibrates, statins) [19–26]. Ligand
activation of PPAR𝛼 induces transcription of many proteins
and enzymes involved in fatty acid uptake (membrane fatty
acid transporters (FATPs), liver fatty acid binding protein (L-
FABP)), intracellular fatty acid transport (L-FABP), and fatty
acid oxidation (L-FABP, CPT1A, CPT2, ACOX1) (review in
[17, 27–29]). Unlike other members of the fatty acid binding
protein family, L-FABP is unique in its broad specificity for
lipidic ligands, binding not only LCFA and LCFA-CoA, but
also a variety of therapeutic agents such as fibrates and their
CoA thioesters (review in [16–18, 30–33]).
Because of their structural resemblance to fatty acids
(Figure 1), we postulated that some of the fatty acid synthesis
inhibitors (esp. TOFA, C75) may also be bounded by L-FABP
and targeted to induce PPAR𝛼 transcription of fatty acid 𝛽-
oxidative enzymes in mitochondria (CPT1A, rate limiting;
CPT2) and peroxisomes (ACOX1, rate limiting). The focus
of this study was to examine the extent to which (i) L-
FABP binds fatty acid synthesis inhibitors; (ii) fatty acid
synthesis inhibitors induce PPAR𝛼 transcription of fatty acid
𝛽-oxidative enzymes (CPT1A, CPT2, ACOX1); (iii) L-FABP
facilitates fatty acid synthesis inhibitor action on PPAR𝛼; (iv)
high glucose impacts L-FABP mediated fatty acid synthesis
inhibitor signaling to PPAR𝛼. These issues were addressed
using purified L-FABP, fluorescent ligand binding assays,
circular dichroism (CD), and cultured primary hepatocytes
from wild-type and L-FABP (−/−) null mice.
2. Materials and Methods
2.1. Materials. Recombinant liver fatty acid binding protein
(L-FABP) and sterol carrier protein-2 (SCP-2) were prepared
as described [34, 35]. Albumin fraction V, fatty acid free
(10% solution for tissue culture), TOFA (5-tetradecyloxy-
2-furancarboxylic acid), C75 (4-methylene-2-octyl-5-oxote-
trahydrofuran-3-carboxylic acid), oleic acid, oleoyl-CoA, D
(+) glucose, dexamethasone, insulin, and acyl CoA syn-
thase from Pseudomonas sp. were purchased from Sigma
(St. Louis, MO, USA). NBD stearate (12-(N-methyl)-N-[(7-
nitrobenz-2-oxa-1,3-diazol-4-yl)-amino]-octadecanoic acid)
was purchased fromAvanti Polar Lipids (Alabaster, Alabama,
USA). ANS (aminonaptholsulfonic acid) was from Cayman
Chemical Company (Ann Arbor, MI, USA). Collagenase B
was from Roche, (Life technologies, Carlsbad, CA, USA).
Dulbecco’s modified Eagle medium DMEM/F12, glucose-
free DMEM, fetal bovine serum, gentamycin, and Hank’s
balanced salt solution free of calcium andmagnesium (HBSS)
were obtained from Gibco/Invitrogen (by Life Technologies,
Carlsbad, CA, USA). RN-ase-free DNase set and RN-easy
kit were obtained from Qiagen GmbH (Hilden, Germany)
and Qiagen Sciences (Maryland, USA), respectively. Taq-
Man, One-Step RT-PCR Master Mix reagents, and TaqMan
Gene Expression Assays for CPT1A (carnitine-palmitoyl-
transferase 1 A), CPT2 (carnitine-palmitoyl-transferase 2),
and ACOX1 (acyl-coenzyme A oxidase 1) were from Applied
Biosystems (by Life Technologies, Carlsbad, CA, USA). Rab-
bit polyclonal antibodies against rat liver fatty acid binding
protein (L-FABP), human sterol carrier protein-2 (SCP-2),
and mouse acyl CoA binding protein (ACBP) were prepared
as described in [36–38]. Rabbit polyclonal antibodies to liver
X receptor-𝛼 (LXR𝛼, sc-1201) and sterol response element
binding protein-1 (SREBP1, sc-367) were obtained from Santa
Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Rabbit
polyclonal antibody to carbohydrate response element bind-
ing protein (ChREBP, ab81958) was purchased from Abcam
PLC (Cambridge, MA, USA). Rabbit polyclonal antibody to
PPAR𝛼 (PA1-822A) was from Pierce Antibodies (Rockford,
IL, USA).
2.1.1. Synthesis, Purification, and Characterization of TOFyl-
CoA and C75-CoA. The active forms of TOFA and C75 are
the respective CoA thioesters, which accumulate within the
cell and are not or only slowly metabolized [10, 12, 39, 40].
Determination ofwhether L-FABP and SCP-2 interactedwith
the fatty acid synthesis inhibitors and/or their CoA thioesters
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required the synthesis of the respective noncommercially
available CoA thioesters. TOFyl-CoAwas prepared by chem-
ical synthesis [41]. Since C75-CoA prepared by chemical
synthesis [41] yields a chemical structure very different
from that obtained enzymatically in vivo, the C75-CoA was
prepared by enzymatic synthesis with long chain acyl CoA
synthase as described in [39, 40]. TOFyl-CoA and C75-CoA
were purified by HPLC as previously described [15]. The
formation of thioester bond was confirmed by disappearance
of the CoA derivatives and appearance of free CoA HPLC
peaks upon alkaline hydrolysis. UV absorbance spectra were
obtained with Cary 100 Scan UV-Visible Spectrophotometer
(Varian, Inc., Palo Alto, CA, USA). To confirm that the
CoA derivatives had the correct molecular weight, TOFyl-
and C75-CoA products were also examined by matrix-
assisted laser desorption ionization time-of-flight (MALDI-
TOF) mass spectrometry utilizing a Shimadzu/Kratos Axima
CFRMALDI-TOFmass spectrometer (Columbia,MD, USA)
in reflectron mode by the Protein Chemistry Laboratory
(Texas A&M University, College Station, TX, USA). Sam-
ples were analyzed by the dried-drop method using 𝛼-4-
hydroxycinnamic acid (Sigma-Aldrich) as the matrix. The
instrument was calibrated with angiotensin (𝑚/𝑧 = 1046.5)
and fibrinopeptide B (𝑚/𝑧 = 1570.7). The calibrants
were obtained from Sigma-Aldrich. For each sample, the
additional labeled peaks corresponded to the parent ion plus
one, two, three, or four potassium ions.
2.2. Ligand Binding Assays
2.2.1. Fluorescent NBD-Stearic Acid Binding to L-FABP and
SCP-2. The binding constants of NBD stearate to L-FABP
and SCP-2 were obtained by titrating a 2mL sample of L-
FABP (25 nM) or SCP-2 (25 nM) in 10mM phosphate buffer
(pH 7.4) with small increments of NBD stearate at 24∘C.
NBD stearate fluorescence emission spectra (515–600 nm)
were recorded using a Varian Cary Eclipse Fluorescence
Spectrophotometer (Varian, Inc., Palo Alto, CA, USA), with
490 nm excitation. The binding curves were constructed by
plotting NBD stearate fluorescence intensity increase (𝐹−𝐹
0
)
versus concentration [NBD stearate], with 𝐹 being fluores-
cence intensity of NBD stearate in the presence of proteins
(at 530 nm for binding to SCP-2 and at 548 nm for binding
to L-FABP) and 𝐹
0
being NBD stearate fluorescence intensity
in buffer (at the same wavelength as for 𝐹). Curve fitting of
the binding curve yielded 𝐹max, the maximum fluorescence
intensity. The dissociation constant 𝐾
𝑑
was calculated from
the slope of double reciprocal plots 1/[1−(𝐹−𝐹
0
)/𝐹max] versus
[NBD-stearate]/[(𝐹 − 𝐹
0
)/𝐹max] as described [20, 42].
2.2.2. Displacement of L-FABP or SCP-2-Bound Fluorescent
Ligands: NBD Stearate and ANS. Advantage was taken of
the fact that NBD-stearic acid bound to L-FABP (two lig-
and binding sites) as well as SCP-2 (single-ligand binding
site) to design a NBD-stearic acid displacement assay that
allowed determination ofwhich fatty acid synthesis inhibitors
or their CoA thioesters bound to these LCFA/LCFA-CoA
binding proteins [20, 42]. Displacement of NBD-stearate
from L-FABP and SCP-2 was determined by incubating L-
FABPor SCP-2 (25 nM in 10mMphosphate buffer)withNBD
stearate (40 nM) for 12min to obtain maximal fluorescence,
followed by titration with increasing amount of ligand. From
the displacement curve, the 𝐾
𝑖
value was calculated as
described [20, 42]. All experiments were carried out with
a thermostated cuvette to maintain temperature at 24∘C
using a circulating water bath. ANS displacement assay was
performed as described [30, 33].
2.2.3. Tyrosine Fluorescence Quenching. Tyrosine fluores-
cence of L-FABP (100 nM) in 10mM phosphate buffer was
monitored by scanning from 290 to 400 nm, with excitation
wavelength 280 nm, before and after small increments of
added binding ligand. The binding curve was constructed
by plotting tyrosine fluorescence intensity at 305 nm versus
concentration of the ligand. 𝐾
𝑑
was then calculated as
described [19, 20].
2.3. Secondary Structure Determination by Circular Dichroism
(CD). Circular dichroism (CD) spectra were obtained utiliz-
ing a JASCO J-815 CD spectrometer (JASCO Analytical
Instruments, Easton,MD,USA). Each sample for CD analysis
contained recombinant rat L-FABP (1𝜇M) in 10mM potas-
sium phosphate (pH 7.4) with or without ligand (10 𝜇M).
Sampleswere scanned from 190 to 250 nmusing the following
conditions: step resolution, 1 nm; bandwidth, 2 nm; sensitiv-
ity, 10mdeg; scan rate, 50 nm/min; and time constant, 1 s.
For each measurement, 10 scans were averaged, background-
subtracted, smoothed using the Means-Movement smooth-
ing method (convolution width, 5) and converted to mean
residue molar ellipticity utilizing the Spectra Manager Ver-
sion 2 software as supplied by the instrument manufacturer
(Spectra Analysis Version 2.03.04, Build 5). The percentage
composition of 𝛼-helices (regular, distorted, total), 𝛽-sheets
(regular, distorted, total), turns, and unordered structures
was determined utilizing the CDPro program as supplied by
the instrument manufacturer using the SDP48 reference set
(soluble + denatured protein) [20, 34]. This program allows
the percentage calculation of various secondary structures by
three different methods: CDSSTR, CONTIN, and SELCON3.
Statistical analysis was performed by one-way analysis of vari-
ance (ANOVA) combined with the Newman-Keuls multiple-
comparisons posttest (GraphPad Prism Version 3.03, San
Diego, CA, USA).
2.4. Wild-Type and L-FABP Gene-Ablated Mice. Wild-type
mice on a C57BL/6N background purchased from Charles
River Laboratories (Wilmington, MA, USA) were obtained
from the National Cancer Institute (Frederick Cancer
Research and Development Center, Frederick, MD, USA). L-
FABP (−/−) null mice were obtained by targeted disruption
of the L-FABP gene [36] and backcrossed to C57Bl/6N
background to the N10 (99.9% homogeneity) generation.
For hepatocyte isolation, livers were collected from male
mice aged 3–6 mo. Mouse protocols were approved by the
Institutional Animal Care and Use Committee (IACUC) at
Texas A&MUniversity.Mice were kept under a constant 12/12
light-dark cycle and had access to food and water ad libitum.
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2.5. Mouse Primary Hepatocyte Isolation and Culture. Mouse
hepatocytes were isolated from livers of male wild-type and
L-FABP null mice as described [43, 44]. To study the effect of
TOFA and C75 at different glucose levels, mouse hepatocytes
were cultured overnight with DMEM/F-12 supplemented
with 5% FBS. Cells were incubated with glucose-free DMEM
supplemented with fatty acid-free BSA (40𝜇M), 100 nM
insulin, 10 nM dexamethasone, and without (no inhibitor) or
with the de novo fatty acid synthesis inhibitors C75 or TOFA
(10 𝜇g/mL) for 30min (1mL/well). Cells were incubated
further for 5 hr with 6 or 20mM glucose without or with the
inhibitors.
2.6. Hepatocyte mRNA and Western Blotting Measurements.
Transcription of key enzymes in mitochondrial (CPT1A and
CPT2) and peroxisomal (ACOX1) 𝛽-oxidation of long chain
fatty acid (LCFA) was determined by rtPCR similarly as
described [44]. Briefly, the RNeasy mini kit from Qiagen
Sciences (MD, USA) was used as per the manufacturer’s
instructions to isolate total RNA, which was then quanti-
fied spectrophotometrically. Quantitative real-time PCR was
performed with an ABI PRISM 7000 Sequence Detection
System (SDS) from Applied Biosystems (Foster City, CA,
USA) to determine relative mRNA expression for CPT1A,
CPT2, and ACOX1. The thermal protocol was as follows:
48∘C for 30min, 95∘C for 10min before the first cycle, 95∘C
for 15 sec, and 60∘C for 60 sec, repeated 40 times. TaqMan
One-StepMasterMix andGene Expression Assays for mouse
CPT1A (Mm 00550438 m1), CPT2 (Mm 00487202 m1), and
ACOX1 (Mm 00443579 m1) were purchased from Applied
Biosystems (Life Technologies, Carlsbad, CA, USA). Tripli-
cates of each sample were analyzed with ABI PRISM 7000
SDS software (Applied Biosystems) to determine ΔCt relative
to a positive control (18S housekeeping gene). The fold
change in the abundance of CPT1A, CPT2, and ACOX1
mRNAs was determined in primary mouse hepatocytes
treated with albumin (40 𝜇M) in the absence and presence of
lipid synthesis inhibitors (C75, TOFA, 10𝜇g/mL) in glucose-
free DMEM medium supplemented with 100 nM insulin,
10 nM dexamethasone, and either 6 or 20mM glucose. The
comparative 2−ΔΔCt calculationmethodwas used as described
inUser Bulletin 2, ABI Prism7000 SDS (AppliedBiosystems),
and earlier [45]. Finally, protein levels of liver fatty acid
binding protein (L-FABP), sterol carrier protein-2 (SCP-2),
acyl CoA binding protein (ACBP), peroxisome proliferator
activated receptor (PPAR𝛼), liver X receptor-𝛼 (LXR𝛼),
carbohydrate response element binding protein (ChREBP),
and sterol response element binding protein (SREBP) were
determined by western blotting as described [44].
2.7. Hepatocyte Cytosolic Glucose Level Measurements. Hepa-
tocytes were plated 2 × 105 per well in 12-well tissue culture
plates (Becton Dickinson and Company, Franklin Lakes, NJ,
USA). After incubation with culture medium containing
TOFAorC75with increasing glucose level as described previ-
ously, hepatocytes were washed quickly with a cold solution
of MgCl
2
(100mM) with 0.1mM phloretin [46]. Cells were
scraped from the dishes with PBS plus protease inhibitor,
and cells were broken open with a probe sonicator (Sonic
Dismembrator 550, Fisher Scientific, Waltham, MA, USA).
Samples were sedimented at 10,000 g, 4∘C for 20min. The
supernatant was used for glucose analysis with the Amplite
Glucose Quantitation Kit (AAT Bioquest, Inc. Sunnyvale,
CA, USA) as instructed by the manufacturer. The number of
cultured primary hepatocytes in each sample was calculated
based on amount of protein (BradfordAssay, Sigma, St. Louis,
MO, USA) compared with reference samples with a known
number of hepatocytes. Cytosolic glucose concentration was
calculated using 7.4 × 10−12 liter/cell as volume of the
hepatocytes [47].
2.8. Hepatocyte Unesterified (Free) LCFA Determination
2.8.1. Lipid Extraction. Cultured mouse hepatocytes were
plated 4 × 105 cells per well in 12-well tissue culture plates.
After incubation with TOFA or C75 at different glucose levels
as described previously, hepatocytes were washed with cold
PBS 4x, scraped with cold PBS (with protease inhibitor), and
homogenized with a probe sonicator (Sonic Dismembrator
550, Fisher Scientific, Waltham, MA, USA). A 20𝜇L sample
was saved for protein analysis using the Bio-Rad protein
assay reagent, (Bio-Rad, Hercules, CA, USA). Samples were
extracted twice with 1% Triton X-100 in pure chloroform
(OmniSolv High purity solvent, 99.9% min. EMD Millipore,
Billerica, MA, USA). The extract was centrifuged for 5–
10 minutes at top speed in a refrigerated microcentrifuge.
The organic phase (lower phase) was collected, dried with a
streamofN
2
, and dried in vacuo for another 30min to remove
chloroform.
2.8.2. Unesterified (Free) LCFA Assay. The LCFA content
of each sample was measured with the Free Fatty Acid
Quantification Kit from BioVision, Inc. (Mountain View,
California, USA) according to manufacturer’s instructions,
using a standard of palmitic acid included in the kit.Thedried
lipids (in Triton X-100) were dissolved in 200 𝜇L of Fatty Acid
Assay Buffer by vortexing extensively for 5min followed by
assay of triplicate 50𝜇L aliquots of the extracted sample.
3. Results
Structural Similarity of Fatty Acid Synthesis Inhibitors to Nat-
urally Occurring Long Chain Fatty Acids (LCFAs) and Fluores-
cent LCFA Analogues.The structure of the fatty acid synthesis
antagonist TOFA has significant similarity to LCFAs such as
the naturally occurring stearic acid and fluorescent NBD-
stearic acid, as evidenced by a long, hydrophobic acyl chain
and a carboxyl terminus with similar total length (Figure 1).
While the fatty acid synthase (FASN) inhibitor C75 also
has a carboxyl terminus, the chain length is much shorter
(11 carbons) than that of stearic acid or TOFA (Figure 1).
Therefore, potential binding of TOFA and C75 to L-FABP
and SCP-2was examined using fluorescent binding assays not
requiring separation of bound from free ligand as described
in Methods. Since the active forms of TOFA and C75 are
thought to be the respective CoA thioesters, binding assays
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Table 1: Binding constants of fatty acids, TOFA, and C75 to L-FABP and SCP-2.
LIGAND
Binding constants (𝜇M)
L-FABP SCP2
Fluorescent fatty acids
NBD stearate 𝐾𝑑1 = 0.018 ± 0.001
𝐾
𝑑2
= 0.055 ± 0.002 0.101 ± 0.003
Endogenous fatty acid
Stearic acid 0.087 ± 0.006(a) ND
Fatty acid synthesis inhibitors
TOFA 0.066 ± 0.003
(a)
0.057 ± 0.004(c) 0.227 ± 0.020
(a)
C75 5.59 ± 0.31(b) not bound(a)
𝐾
𝑖
was determined by displacing protein-bound NBD-stearic acid (a) or ANS (b) as in Methods. (c),𝐾
𝑑
was determined by L-FABP tyrosine quenching. ND:
not determined. Values are the mean ± SEM, 𝑛 = 3.
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Figure 2: Representative binding curves of stearic acid binding to L-FABP (panel a) and SCP2 (panel b). NBD-stearic acid binding curves
were obtained as described in Methods. Briefly, a 2mL sample of L-FABP (25 nM) or SCP-2 (25 nM) in 10mM phosphate buffer (pH 7.4) was
titrated with small increments of NBD stearate at 24∘C (Methods). NBD-stearate fluorescence emission spectra (515–600 nm) were recorded
with 490 nm excitation.𝐹: fluorescence intensity of NBD stearate in the presence of proteins (at 530 nm for binding to SCP-2 and at 548 nm for
binding to L-FABP) and 𝐹
0
being NBD-stearate fluorescence intensity in buffer (at the same wavelength as for 𝐹). Insets are double reciprocal
plots of the fluorescence binding data in the same panel.
were performed with L-FABP because it binds both LCFA
and LCFA-CoA, trafficks to and binds PPAR𝛼 within the
nucleus, and enhances LCFA and LCFA-CoA transport into
nuclei (review in [16, 17, 48–50]). SCP-2 was used as a
control because it binds both LCFA and LCFA-CoA but is
not significantly distributed to nuclei or interact with PPAR𝛼
(review in [16, 17, 48–50]).
NBD-Stearic Acid Binds with Higher Affinity to L-FABP than
SCP-2. NBD-stearic acid, a fluorescent poorly metabolizable
analogue of the natural LCFA stearic acid (Figure 1) directly
monitored binding to L-FABP and SCP-2 as in Methods.
While NBD-stearic acid fluoresces weakly in aqueous buffer,
emission increases dramatically when being bound to
the ligand binding sites of L-FABP or SCP-2 (Figure 2).
With increasing NBD-stearic acid, fluorescence of L-FABP-
(Figure 2(a)) and SCP-2 (Figure 2(b)) bound NBD-stearic
acid increased towards saturation. Double reciprocal analysis
of the binding curves showed that L-FABP has two binding
sites (Figure 2(a), inset), while SCP-2 has a single NBD-
stearic acid binding site (Figure 2(b), inset). Analysis of
multiple binding curves allowed quantitative determination
of L-FABP’s and SCP-2’s binding characteristics to NBD-
stearic acid. The high affinity L-FABP binding site (𝐾
𝑑1
=
0.017 𝜇M) was nearly 4-fold higher affinity than the lower
affinity binding site (𝐾
𝑑2
= 0.055 𝜇M), while SCP-2 bound
NBD-stearic acid with a somewhat weaker affinity near
0.1 𝜇M (Table 1).
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Figure 3: Displacement of L-FABP- and SCP2-bound NBD-stearic acid by TOFA (panels a and b) and C75 (panels c and d). NBD-stearic
acid displacement assays were performed as shown in Methods. L-FABP or SCP-2 (25 nM in 10mM phosphate buffer) was incubated with
NBD stearate (40 nM) for 12min at 24∘C to obtain maximal fluorescence, then titrated with increasing amount of ligand. Mean ± SEM, 𝑛 = 3.
TheFatty Acid Synthesis Inhibitor TOFA, and Less So C75, Dis-
placed Bound Fluorescent Ligands from L-FABP and SCP-2. A
NBD-stearic acid displacement assay (Methods) revealed that
TOFA significantly displaced L-FABP bound NBD-stearic
acid, as shown by fluorescence decreasing to 40% at 650 nM
TOFA (Figure 3(a)). A 𝐾
𝑖
= 0.066 𝜇M was determined for
TOFA displacing NBD-stearic acid from L-FABP (Table 1).
Comparison with the 𝐾
𝑑
s of the high and low affinity NBD-
stearic acid binding sites of L-FABP indicated that both
stearic acid and TOFA preferentially displaced NBD-stearic
acid from the weaker affinity LCFA binding site (Table 1).
TOFA also displaced NBD-stearic acid bound to SCP-2
(Figure 3) with a 𝐾
𝑖
= 227 ± 20 nM, about half of the affinity
forNBD-stearic acid binding to SCP-2 (Table 1).Thus, the𝐾
𝑖
s
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for TOFA displacing NBD-stearic acid from L-FABP and
SCP-2 were in the same range as those for endogenous LCFAs
such as stearic acid (Table 1).
In contrast, C75 displacement of NBD-stearic acid bound
to L-FABP was weaker (Figure 3(c)) and barely detectable
from SCP-2 (Figure 3(d)). Since the C75 more weakly dis-
placed a strongly bound ligand such as NBD-stearic acid,
displacement was also measured with the weaker affinity
fluorescent ligand aminonaptholsulfonic acid (ANS). L-FABP
bound ANS, a ligand significantly larger than NBD-stearic
acid, at only a single site with𝐾
𝑑
s of 1.96±0.09 𝜇M, consistent
with earlier findings [30, 31]. C75 displaced ANS from L-
FABP with a 𝐾
𝑖
of 5.59 ± 0.31 𝜇M, thereby confirming
weaker binding than observed with the NBD-stearic acid
displacement assay.
Taken together, these findings suggested that TOFAwas a
good high-affinity ligand for L-FABP and somewhat less than
so for SCP-2. In contrast, C75was aweaker ligand for L-FABP,
and binding to SCP-2 was barely detectable.
Synthesis, Purification, and Characterization of TOFyl-CoA
andC75-CoA. Since the active forms of TOFA andC75within
living cells are thought to be the respective CoA thioesters,
it was important to also determine if L-FABP and/or SCP-2
bound the respective CoA thioesters [12, 39, 40]. However,
TOFyl-CoA and C75-CoA are not commercially available.
Therefore, TOFyl-CoA (chemical synthesis) and C75-CoA
(chemical and enzymatic synthesis) were prepared and puri-
fied by HPLC as described in Methods. Formation of the
respective thioester bond and purity were confirmed by
(1) UV absorbance spectra detecting the thioester bonds
near 260 nm for TOFyl-CoA and C75-CoA (Figure 4(a)); (2)
detection of single-absorbance peaks at 260 nm with reten-
tion times near 13 and 9min for TOFyl-CoA and C75-CoA in
HPLC chromatograms (Figure 4(b)); and (3) disappearance
of the CoA derivatives and appearance of free CoA HPLC
peaks at earlier retention times upon alkaline hydrolysis (not
shown). Matrix-assisted laser desorption ionization time-
of-flight (MALDI-TOF) mass spectrometry confirmed the
expected correct mass for TOFYL-CoA (Figure 5(a), 𝑚/𝑧 =
1074.69) and C75-CoA (Figure 5(b), 𝑚/𝑧 = 1022.51). For
each sample, the additional labeled peaks corresponded to the
parent ion plus one, two, three, or four potassium ions.
Binding of CoA Thioesters of Fatty Acid Synthesis Inhibitors
to L-FABP and SCP-2: NBD-Stearic Acid Displacement Assay.
Since TOFyl-CoA did not decrease the fluorescence intensity
of NBD-stearic acid bound to L-FABP, this would at first
glance suggest that TOFyl-CoA did not bind to L-FABP
(Figure 6(a)). Closer inspection of the L-FABP bound NBD-
stearic acid emission spectra, however, revealed that TOFyl-
CoA shifted the maximal emission wavelength of L-FABP-
bound NBD-stearic acid from 553 to 539 nM (Figure 6(a)),
suggesting that TOFyl-CoA did bind to L-FABP. This
shift was confirmed by adding increasing concentrations of
TOFyl-CoA, which resulted in blue shifting of the emission
maximum (i.e., shorter wavelength) of L-FABP-bound NBD-
stearic acid (Figure 6(b)). Concomitantly, increasing concen-
trations of TOFyl-CoA increased the emission intensity of
Table 2: Binding parameters for L-FABP and SCP2 to CoA interact-
ing with fatty acid and fatty acid synthesis inhibitor CoA thioesters.
Binding constants (𝜇M)
L-FABP SCP2
Stearoyl-CoA 0.46 ± 0.03(a) ND
TOFyl-CoA 0.053 ± 0.004(c) 0.004 ± 0.001(a)
C75-CoA 25.9 ± 3.9(b) Not bound(a)
𝐾
𝑖
was determined by displacing protein-boundNBD-stearic acid (a) orANS
(b) or by intrinsic L-FABP tyrosine quenching (c) as in Methods. ND: not
determined. Values are the mean ± SEM, 𝑛 = 3.
NBD-stearic acid bound to L-FABP by ∼15% (Figure 6(c)). It
should be noted that these shifts in emission maximum and
intensity were not due to TOFyl-CoA forming micelles with
NBD-stearic acid since these changes were not observed in
the absence of L-FABP (data not shown).
In contrast, TOFyl-CoA completely displaced SCP-2-
bound NBD-stearic acid, as shown both by the displacement
curve (Figure 7(a)) and decreased emission spectra of NBD-
stearic acid (Figure 7(b)). TOFyl-CoA was also very efficient
in displacing SCP-2-bound NBD-stearic acid as shown by
a 𝐾
𝑖
= 4 ± 1 nM (Table 2). In contrast, C75-CoA did not
displace NBD-stearic acid from L-FABP; that is, there was
no alteration in emission spectra (not shown). Likewise,
C75-CoA did not displace NBD-stearic acid from SCP-2
(Figure 7(c)).
Taken together, these data suggested that TOFyl-CoA did
not actually displace NBD-stearic acid from L-FABP, but by
binding to L-FABP the TOFyl-CoA instead shifted NBD-
stearic acid to amore hydrophobic environmentwithin the L-
FABP binding pocket. In contrast, TOFyl-CoA efficiently dis-
placed NBD-stearic acid from SCP-2, while C75-CoA did not
displace NBD-stearic acid bound to either L-FABP or SCP-2.
Confirmation of TOFyl-CoA Binding to L-FABP. To further
confirm that TOFyl-CoA bound to L-FABP, an intrinsic
L-FABP tyrosine quenching assay was used as described in
Methods. Both TOFA and TOFyl-CoA efficiently quenched
L-FABP tyrosine emission (Figures 8(a) and 8(b)). Analysis of
multiple L-FABP tyrosine quenching curves yielded binding
affinities to L-FABP of 𝐾
𝑑
= 57 ± 4 nM for TOFA (Table 1)
which was similar to that obtained by displacing NBD-stearic
acid𝐾
𝑑
= 66± 3 nM for TOFA (Table 1). Tyrosine quenching
also determined a similar affinity of L-FABP for TOFyl-CoA
as shown by 𝐾
𝑑
= 53 ± 4 nM (Table 2). In contrast, C75-
CoA very weakly quenched L-FABP tyrosine fluorescence
emission (Figure 8(c)). Very weak binding of C75-CoA to
L-FABP was confirmed by the ANS displacement assay
(see Methods) wherein C75-CoA displaced ANS bound to
L-FABP with a 𝐾
𝑖
of 25.9𝜇M (Table 2).
Taken together with the preceding data, these findings
demonstrated that although L-FABP bound both fatty acid
synthesis inhibitors and their CoA thioesters, these ligands
were bound preferentially in the order TOFA, TOFyl-CoA >
C75 > C75-CoA.
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Figure 4: UV spectra and HPLC analysis of TOFA-CoA and C75-CoA. Ultraviolet spectra of TOFyl-CoA and C75-CoA were obtained with
a Cary 100 Scan UV-Visible Spectrophotometer (Varian, Inc., Palo Alto, CA, USA) as described in Methods. TOFyl-CoA and C75-CoA were
purified by HPLC as previously described [15]. When the final purified TOFyl-CoA and C75-CoA were reapplied to the HPLC column,
representative HPLC runs detected only single absorbance peaks at 260 nm for TOFyl-CoA and C75-CoA with retention times of 13 and
9min, respectively.
Effect of TOFA, C75, andTheir CoAThioesters on L-FABP Sec-
ondary Structure. Since ligand and coactivator/corepressor-
induced conformational changes are a hallmark of ligand-
induced nuclear receptors such as PPAR𝛼 [17, 27, 51, 52], the
impact of the fatty acid synthesis inhibitors and their CoA
thioesters on L-FABP secondary structure was determined by
circular dichroism as described in Methods.
Although L-FABP bound both TOFA and TOFyl-CoA
with high affinity (Tables 1 and 2), only TOFA significantly
altered L-FABP secondary structure. While TOFA binding
did not alter the proportion of 𝛼-helix (Figure 9(a)) or
unordered structure (Figure 9(c)), the proportion of all types
of 𝛽-sheet was increased (Figure 9(b)) concomitant with
decreased turn structure (Figure 9(c)).
Likewise, while L-FABP more modestly bound C75 and
C75-CoA with lower affinity than TOFA or TOFyl-CoA
(Table 1), C75 did not alter L-FABP secondary structure but
C75-CoA significantly altered L-FABP structure (Figure 9).
In contrast, C75-CoA decreased the proportion of all types of
𝛼-helix (Figure 9(a)) but increased the proportion of all types
of 𝛽-sheet (Figure 9(b)) without altering the amount of turn
or unordered structures (Figure 9(c)).
Taken together these findings demonstrated that alth-
ough L-FABP bound the fatty acid synthesis inhibitors and
their CoA thioesters, only TOFA and C75-CoA significantly
altered L-FABP’s secondary structure.
Mouse Primary Hepatocytes as a Model for Examining the
Impact of LCFA Synthesis Inhibitors and L-FABP on PPAR𝛼
Transcriptional Activity. While there are limitations to any in
vitro model, cultured primary mouse hepatocytes are a
physiologically relevant and more controlled system without
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Figure 5: Mass spectral characterization of CoA derivatives of TOFA and C75. HPLC purified TOFYL-CoA (Panel a, 𝑚/𝑧 = 1074.69)
and C75-CoA (Panel b, 𝑚/𝑧 = 1022.51) were examined by matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass
spectrometry utilizing a Shimadzu/Kratos Axima CFRMALDI-TOF mass spectrometer (Columbia, MD, USA) in reflectron mode. Samples
were analyzed by the dried-drop method using 𝛼-4-hydroxycinnamic acid (Sigma-Aldrich) as the matrix. The instrument was calibrated
with angiotensin (𝑚/𝑧 = 1046.5) and fibrinopeptide B (𝑚/𝑧 = 1570.7). The calibrants were obtained from Sigma-Aldrich. The parent ions
for TOFyl-CoA and C75-CoA were obtained at𝑚/𝑧 = 1022.51 (a) and𝑚/𝑧 = 1074.69 (b), respectively.
competition by other tissues for LCFA synthesis inhibitors,
organ-specific cross talk, or endocrine influences [53]. Our
labs previously established that primary mouse hepato-
cytes maintained expression of key proteins, enzymes, and
receptors involved in the uptake of LCFAs (FATP5, GOT,
FATP2, FATP4) and glucose (GLUT2, GLUT1, glucokinase,
insulin receptor) similar to those in liver for 2-3 days
in culture [43, 54–56]. Mouse primary hepatocytes also
maintained expression of cytosolic LCFA/LCFA-CoA bind-
ing/transport proteins including L-FABP (Figure 10(a)), SCP-
2 (Figure 10(b)), and ACBP (Figure 10(c)). Finally, mouse
primary hepatocytes’ expression of PPAR𝛼 (Figure 11(a)),
LXR𝛼 (Figure 11(b)), and CHREBP (Figure 11(c)) was also
similar to liver for 3 days in culture. SREBP-1 expression was
the same as liver and constant for 1 day, decreasing slightly
thereafter (Figure 11(c)). Thus, for all subsequent studies of
fatty acid synthesis inhibitor effects (in the context of the
presence or absence of L-FABP) on PPAR𝛼 transcriptional
activity of fatty acid 𝛽-oxidative enzymes the mouse primary
hepatocytes were cultured ≤2 days.
Impact of Fatty Acid Synthesis Inhibitors on PPAR𝛼 Trans-
cription of Mitochondrial (CPT1A, CPT2) and Peroxisomal
(ACOX1) Fatty Acid 𝛽-Oxidative Enzymes in Wild-Type
Mouse Primary Hepatocytes: Role of Glucose. When hepato-
cytes were cultured in medium with normal physiological
glucose (6mM), neither TOFA nor C75 significantly altered
PPAR𝛼 transcription of CPT1A (Figure 12(a), black bars),
CPT2 (Figure 12(c), black bars), or ACOX1 (Figure 12(e),
black bars). In contrast, at high (20mM) glucose in the
culture medium both TOFA and C75 induced PPAR𝛼
transcription of CPT1A 2 (Figure 12(a), open bars), CPT2
(Figure 12(c), open bars), and ACOX1 (Figure 12(e), open
bars). Thus, high glucose conferred on TOFA and C75 the
ability to induce PPAR𝛼 transcriptional activity.
Fatty Acid Synthesis Inhibitors Induce PPAR𝛼 Transcription
of Mitochondrial (CPT1A, CPT2) and Peroxisomal (ACOX1)
Fatty Acid 𝛽-Oxidative Genes in Primary Hepatocytes from
Mice: Role of L-FABP. At physiologically normal glucose
(6mM) in the culturemedium, L-FABP gene ablation did not
alter the lack of effect of TOFA or C75 on PPAR𝛼 transcrip-
tion of CPT1A (Figure 12(b), black bars), CPT2 (Figure 12(d),
black bars), or ACOX1 (Figure 12(f), black bars). However, at
high glucose (20mM) L-FABP gene ablation abolished the
ability of TOFA and C75 to activate PPAR𝛼 transcription
(Figures 12(b), 12(d), and 12(f), open bars). On the contrary,
at 20mM glucose and in the presence of TOFA the loss of L-
FABP decreased by nearly 50% the PPAR𝛼 transcription of
CPT1A (Figure 12(b), open bars), CPT2 (Figure 12(d), open
bars), or ACOX1 (Figure 12(f), open bars).
This loss of the ability of fatty acid synthesis inhibitors
to induce PPAR𝛼 transcriptional activity in the context of
high glucose was associated with complete loss of L-FABP
(Figure 10(d)). L-FABP gene ablation did not downregulate
the level of the other LCFA/LCFA-CoA binding proteins,
SCP-2 (Figure 10(e)), and ACBP (Figure 10(f)). Instead, the
level of SCP-2 was unchanged (Figure 10(e)) while that of
ACBP was actually upregulated (Figure 10(f)) in L-FABP null
hepatocytes.
Effect of High Glucose in the CultureMedium on Cytosolic Glu-
cose: Impact of Fatty Acid Synthesis Inhibitors. High glucose
enhances L-FABP interaction with PPAR𝛼, and nucleo-
plasmic glucose levels are similar to cytoplasmic [49, 57].
Therefore, the possibility that high glucose in the culture
medium raised intracellular glucose levels was examined in
the absence or presence fatty acid synthesis inhibitors.
When mouse primary hepatocytes were cultured in
medium without fatty acid synthesis inhibitors but with
normal physiological (6mM) glucose, cytosolic glucose was
near 2mM (Figure 13(a), black bar, no inhibitor). Increasing
glucose level from 6 to 20mM, in the absence of fatty acid
synthesis inhibitors, increased cytosolic glucose in parallel by
nearly 4-fold to 9mM (Figure 13(a), no inhibitor).
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Figure 6: Effect of TOFyl-COA on fluorescence emission characteristics of L-FABP-bound NBD-stearic acid. NBD-stearic acid, bound to
L-FABP as in Figure 3, was excited at 490 nm and fluorescence emission spectra obtained before and after addition of TOFyl-CoA (Methods).
Panel (a): fluorescence emission spectra of L-FABP- (25 nM) bound NBD stearate (80 nM) without (filled circles) and with (open circles) of
TOFyl-CoA (1500 nM).With increasing TOFyl-CoA concentration, the emission maximum of L-FABP-bound NBD stearate shifted to lower
wavelength (panel b), and fluorescence intensity increased (panel c).
Interestingly, in the presence of TOFA or C75 in the
culture medium containing normal physiological (6mM)
glucose, mouse primary hepatocyte cytosolic glucose was
increased ∼2-fold to 4mM (Figure 13(a), black bars, TOFA or
C75). In the presence of TOFA or C75with increasing glucose
(from 6 to 20mM) the cytosolic glucose was increased in
parallel by nearly 5- and 4-fold to 20 and 13mM, respectively,
(Figure 13(a), open bars, TOFA or C75).
Taken together, these data showed that high glucose
(20mM) alone or fatty acid synthesis inhibitors (TOFA or
C75) alone increased cytoplasmic glucose to about 45%
or 80% compared to that of extracellular glucose. High
glucose together with TOFA or C75 increased cytoplasmic
glucose even more such that it was nearly the same as that
in the culture medium. Thus, cultured primary hepatocyte
cytosolic glucose level was about half of that in the culture
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Figure 7: Effect of TOFyl-CoA and C75-CoA on NBD stearic binding to SCP-2. SCP-2 (25 nM in 10mM phosphate buffer) was incubated
with NBD-stearic acid (40 nM) for 12min at 24∘C to obtain maximal fluorescence. The solution was titrated with increasing amount of
ligand (TOFyl-CoA or C75-CoA). TOFyl-CoA displaced SCP2-bound NBD stearate (panel a, with representative spectra in panel b). Panel
(b), from top to bottom: shot dash line: NBDS+SCP2; dash-double dot-dash line: NBDS+SCP2+TOFyl-CoA (10 nM); long dashed line:
NBDS+SCP2+TOFyl-CoA (100 nM); solid line: NBDS; dotted line: NBDS+TOFyl-CoA (100 nM). C75-CoA did not displace SCP2-bound
NBD-stearate (panel c). Panel (a), mean ± SEM, 𝑛 = 3.
medium but highly responsive to the extracellular glucose
concentration. Further, fatty acid synthesis inhibitors (TOFA,
C75) precluded incorporation of glucose-derived acetyl CoAs
into fatty acids, and thus intracellular glucose increased to
near extracellular levels.
Fatty Acid Synthesis Inhibitors Had Little Effect on Cellular
Mass of Unesterified Fatty Acids. Although the majority
(>93%) of LCFAs synthesized de novo from glucose are
saturated (C14 : 0, C16 : 0, C18 : 0) [58] and do not bind to
PPAR𝛼 [19, 20, 24], the remaining 7% (primarily C18 : 1n-
9 and C18 : 2n-6) are bound and/or weakly activate PPAR𝛼
[20, 59–63]. Althoughmonounsaturated LCFAs such as 18:1n-
9 have little effect on PPAR𝛼 activity or PPAR𝛼-regulated
genes in cultured primary hepatocytes [64], a previous study
suggested that de novo synthesized endogenous LCFA may
also be PPAR𝛼 agonists in liver as demonstrated in fatty-acid
synthase knockout in liver of mice [65]. Therefore, the possi-
bility that inhibition of de novo fatty acid synthesis (especially
by TOFA) at high glucose led to the decreased cellular levels
of unesterified fatty acids was examined. Neither TOFA nor
C75 significantly impacted the unesterified fatty acid level in
mouse primary hepatocytes cultured with normal physiolog-
ical glucose in the medium (Figure 13(b), black bars). High
glucose (20mM) alone decreased cellular unesterified fatty
acid level slightly, an effect not further exacerbated by de novo
fatty acid synthesis inhibitors (Figure 13(b), open bars).Thus,
overall the inhibitors of de novo fatty acid synthesis did not
significantly alter hepatocyte levels of unesterified fatty acids.
The maintenance of a near constant level of unesterified fatty
acid was likely due to the presence of exogenous fatty acids
taken up from the medium and/or to release of fatty acids
from intracellular lipid storage droplets.
4. Discussion
To help explain some of the paradoxical findings involving
fatty acid synthesis inhibitors, we hypothesized, based on
their structural similarity to fatty acids, that theymaymediate
part of their action through the L-FABP signaling to PPAR𝛼
in the nucleus. Experimental findings presented herein make
the following significant contributions to our understand-
ing of the mechanism(s), whereby the fatty acid synthesis
inhibitors may also act by affecting PPAR𝛼-regulated expres-
sion of fatty acid oxidative enzymes in liver.
First, L-FABP bound fatty acid synthesis inhibitor TOFA
and its thioester TOFyl-CoA. L-FABP affinities for TOFA
and TOFyl-CoA were in the same range as those for potent
PPAR𝛼 activators such as n-3 polyunsaturated fatty acids
and fenofibrate [30, 31, 66–69]. It is important to note,
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Figure 8: TOFA, TOFyl-CoA, andC75-CoAbinding to L-FABP as determined by quenching of intrinsic L-FABP tyrosine quenching. L-FABP
tyrosine quenching by TOFA (panel a), TOFyl-CoA (panel b), and C75-CoA (panel c) was determined as described in Methods. Tyrosine
fluorescence emission of L-FABP (100 nM) in 10mM phosphate buffer (pH = 7.4) was monitored by scanning from 290 to 400 nm, with
excitation wavelength 280 nm, before and after small increments of added binding ligand. The binding curve was constructed by plotting
percentage of tyrosine fluorescence intensity remaining at 305 nm versus concentration of the ligand. Panel (a) and (b), mean ± SEM, 𝑛 = 3.
however, that TOFA and TOFyl-CoA bound L-FABP in a
manner similar to, but also somewhat different, from that
of analogous chain length natural LCFAs, LCFA-CoAs, and
LCFA derivatives (HETEs, prostaglandins) and a variety
of peroxisome proliferator agents (fibrates, fibroyl-CoAs,
eicosatetraynoic acid, WY14,643, BRL48,482) [18, 66–68,
70–72]. Our finding of two NBD-stearic acid binding sites
on L-FABP was consistent with most other fluorescence,
isothermal titration microcalorimetry, and NMR studies,
which also detected two-LCFA or LCFA-CoA binding sites
on L-FABP [18, 66, 68, 71–73]. However, our finding that both
TOFA and TOFyl-CoA bound to L-FABP but only TOFA
displaced L-FABP-boundNBD-stearic acid suggests the pres-
ence of an additional site on L-FABP that bound TOFyl-CoA
but not NBD-stearic acid. Consistent with this possibility,
radioligand binding, NMR, and X-ray crystallography all
detect the presence of additional site(s) that binds LCFA or
smaller molecules [74–79].
Second, L-FABP also bound the fatty acid synthesis
inhibitor C75 and its thioester C75-CoA but more weakly
than TOFA or its thioester. C75 and C75-CoA were less able
to displace bound NBD-stearic acid or ANS. This finding
was consistent with L-FABP less strongly binding 11-12 atom
chain-length fatty acids and/or their CoA thioesters than
their longer chain counterparts [80, 81]. This suggested that
perhaps C75 and/or C75-CoA might also interact with the
previously mentioned additional binding site on L-FABP
without altering NBD-stearic acid binding or L-FABP tyro-
sine emission [72, 82]. Earlier studies suggested the presence
of an additional ligand binding site in L-FABP [74–79].
Regardless, however, it is important to note that while L-
FABP’s affinity for C75 and C75-CoA was significantly lower
than that of TOFA and its thioesters, nevertheless these
affinities were in the range of the less potent fibrate activators
of PPAR𝛼 such as bezafibrate and clofibrate [30, 31, 33, 69].
Third, L-FABP not only binds the fatty acid synthesis
inhibitors, but several (TOFA, C75-CoA) also altered L-
FABP’s secondary structure, suggesting that this in turn may
facilitate L-FABP ligand signaling to PPAR𝛼. In support of
this possibility L-FABP directly binds to PPAR𝛼 [17, 33,
49, 83]. Further, fatty acid or fibrate binding alters L-FABP
structure to stabilize the ligand portal region of L-FABP for
directly channeling bound ligands for optimal transfer to
PPAR𝛼 [17, 33, 49, 83, 84]. Although it has been speculated
that PPAR𝛼 may bind TOFA, to date there have been no
reports determining the possibility that TOFA, C75, or their
CoA thioesters bind PPAR𝛼. However, an examination of
their structures (Figure 1) shows that these ligands contain
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Figure 9: Selective fatty acid synthesis inhibitors and their CoA thioesters alter L-FABP secondary structure determined by circular dichroism
(CD). L-FABP (1𝜇M) was incubated in the absence or presence of 10𝜇M ligand for 10min at 25∘C. Circular dichroism (CD) spectra were
obtained utilizing a JASCO J-815 CD spectrometer (JASCO Analytical Instruments, Easton, MD, USA). Each sample spectrum represented
the average of ten scans, and each sample spectrumwas baseline corrected. Secondary structurewas determined using theCONTIN algorithm
as supplied by the instrument manufacturer. Statistical significance of secondary structure differences was determined by one-way ANOVA
with the Newman-Keuls posttest (𝑛 = 3). ∗𝑃 < 0.05 for L-FABP + ligand versus rat L-FABP (no ligand); ∗∗𝑃 < 0.01 for rat L-FABP + ligand
versus rat L-FABP (no ligand); ∗∗∗𝑃 < 0.001 for rat L-FABP + ligand versus rat L-FABP (no ligand).
C10 to C14 carbon chains. Radioligand binding assays reveal
that 10–14 carbon fatty acids are bound by PPAR𝛼 (and more
weakly by other PPARs) and activate PPAR𝛾 [85, 86]. On this
basis, it can be hypothesized that TOFA, C57, and/or their
respective CoA derivatives may also bind to PPAR𝛼 such that
induction was significantly potentiated by high glucose in the
culture medium, albeit requiring L-FABP.
Fourth, TOFA and C75 induced PPAR𝛼 transcription of
mitochondrial (CPT1A, CPT2) and peroxisomal (ACOX1)
fatty acid 𝛽-oxidative enzymes in cultured primary mouse
hepatocytes. Thus, TOFA stimulated CPT1 activity and fatty
acid oxidation not only by reducing malonyl-CoA levels as
suggested earlier [10], but also by inducing PPAR𝛼 transcrip-
tion of CPT1 as well as other LCFA 𝛽-oxidative enzymes.
In support of this finding in mouse hepatocytes, TOFA also
transactivated PPAR𝛼 in COS7 cells and increased expression
of PPAR𝛼 itself regulated by PPAR𝛼 ligands [87, 88]. Like-
wise, C75 stimulated CPT1A activity and fatty acid oxidation
not only by binding to CPT1 to prevent inhibition bymalonyl
CoA or by reducing ACC expression as hypothesized earlier
[3, 13], but also by inducing PPAR𝛼 transcription of CPT1A
and other LCFA 𝛽-oxidative enzymes (CPT2, ACOX1) in
the nucleus. In contrast to TOFA and C75, cerulenin has
only a single carbonyl group, is not amphipathic, does not
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Figure 10: Expression of LCFA and LCFA-CoAbinding proteins in culturedmouse primary hepatocytes. Primary hepatocytes fromwild-type
and L-FABP null mice were isolated from mouse livers and maintained in culture for up to four days as described in Methods. Quantitative
western blotting was performed by comparison to a standard curve of known amounts of the respective recombinant L-FABP, SCP-2, or
ACBP on the same blot as described in Methods. Quantitative western blots were obtained as a function of increasing time for wild-type
hepatocytes in culture: (a) L-FABP; (b) SCP-2; and (c) ACBP. Time 0 = concentration in liver while time of 1–4 days indicates time in culture.
For determining the effect of L-FABP gene ablation on expression of these proteins, quantitative western blots of (d) L-FABP; (e) SCP-2; and
(f) ACBP were also obtained for hepatocytes from wild-type (WT) and L-FABP null (KO) hepatocytes after three days in culture. Mean ±
SEM, 𝑛 = 3–6.
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Figure 11: Expression of key nuclear receptors involved in fatty acid and glucose metabolism as a function of time. Primary hepatocytes were
isolated from mouse livers and maintained in culture for up to four days as described in Methods. Representative western blots relative to
a housekeeping protein (COX-1) are shown in the inserts. Quantitative analysis of multiple western blots relative to housekeeping protein
was shown as black bars for PPAR𝛼 (Panel a), LXR𝛼 (Panel b), SREBP1 (Panel c), and ChREBP (Panel d) as described in Methods. Time 0 =
concentration in liver while time of 1–4 days indicates time in culture. Mean ± SEM, 𝑛 = 3–6.
increase CPT1 activity, and does not transactivate PPAR𝛼 in
COS7 cells [13, 88]. Taken together, these findings suggest
that fatty acid synthesis inhibitors such as TOFA and C75
may exert their lipid lowering effects at least in part by
inducing PPAR𝛼 transcription of CPT1A and other fatty acid
𝛽-oxidative enzymes in tissues such as liver.
Fifth, TOFA and C75 induced PPAR𝛼 transcription of
fatty acid 𝛽-oxidative enzymes only when themouse primary
hepatocytes were cultured in the presence of high glucose in
the medium. In support of this finding, previous studies have
demonstrated that TOFA and C75 increased CPT1A activity
and fatty acid oxidation in rat hepatocytes cultured in media
containing high glucose (11mM) [10, 12–14]. Interestingly, a
variety of other LCFAs (PUFA > MUFA > saturated) and
xenobiotics (fibrates, Wy-14643) activate PPAR𝛼 transcrip-
tion when hepatocytes were cultured in medium containing
high levels of glucose (11–28mM) [44, 89–97]. Unfortunately,
the effects of these L-FABP ligands at normal physiological
(6mM) glucose were not reported. Although TOFA trans-
activated PPAR𝛼 in COS7 cells cultured in commercially
available DMEM medium [88], it is not clear which of
the available DMEM formulations (i.e., 25, 5.6, or 0mM
glucose) was used.However, studies fromour laboratory have
shown that other lipidic ligands (arachidonic acid, clofibrate)
transactivate PPAR𝛼 much more with increasing glucose in
DMEM culture medium [98]. It is important to note that
the potentiation of TOFA and C75 induction of PPAR𝛼 tran-
scription of fatty acid 𝛽-oxidative enzymes at high glucose
correlated with high cytosolic glucose. Cytosolic glucose is
>100-fold lower than outside inmost peripheral cells [46, 98–
100], but liver cytosolic glucose is much higher (∼4mM)
[101, page 59], [102, 103], consistent with the 2mM glucose
in hepatocytes cultured with normal physiological glucose
(6mM) shown herein. The cytosolic glucose concentration
in hepatocytes higher than most other cell types is due to
the presence of a higher 𝐾
𝑚
glucose transporter (GLUT2),
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Figure 12: Effect of TOFA and C75 on CPT1, CPT2, and ACOX1 gene expression in cultured mouse primary hepatocytes isolated from livers
of wild-type (WT, L-FABP (+/+)) and null [(L-FABP (−/−)] mice. Hepatocytes isolated from wild-type [WT, L-FABP (+/+)] or gene-ablated
[null, L-FABP (−/−)]micewere preincubated for 30minwith 10𝜇g/mLTOFAorC75 in serum-free culturemediumbefore addition of glucose
(6 or 20mM) as described in Methods. Total RNA was isolated from hepatocytes 5 hr after glucose addition and used for quantitative real-
time PCR.The fold change in CPT1A (a, b), CPT2 (c, d), ACOX1 (e, f) mRNA levels was determined relative to internal control housekeeping
gene as described inMethods. Values for each genotype were expressed relative to [Alb + 6mM glucose] within that genotype. Panels (a), (b):
CPT1A mRNA fold changes in WT and L-FABP null hepatocytes; (c), (d): CPT2 mRNA fold changes in WT and L-FABP null hepatocytes;
(e), (f): ACOX1 mRNA fold changes in WT and L-FABP null hepatocytes. Mean ± SEM, 𝑛 = 3.
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Figure 13: Cytosolic glucose (panel a) and free fatty acid (LCFA, panel b) levels in mouse primary hepatocytes cultured with and without
TOFA or C75. Hepatocytes were incubated with TOFA or C75 (10𝜇g/mL) with 6 or 20mM glucose (Section 2). Cytosolic glucose level was
then determined as in Methods. Briefly, hepatocytes were washed quickly with ice old solution of MgCl
2
(100mM) with 0.1mM phloretin.
Cells were then homogenized with a probe sonicator and, after centrifugation, the supernatant was used for glucose analysis with the Amplite
Glucose Quantitation Kit as instructed by the manufacturer. For LCFA determination, hepatocyte homogenate was extracted twice with 1%
Triton X-100 in pure chloroform.The organic phase was collected, and the FFA content of each sample was measured with the Free Fatty Acid
Quantification Kit from BioVision, Inc. according to manufacturer’s instructions using enclosed palmitic acid as standard. Mean ± SEM,
𝑛 = 3.
a higher 𝐾
𝑚
hexokinase (glucokinase), different insulin
sensitivity, and different metabolic activity [101, page 59],
[102, 103]. High glucose in the medium (20mM) significantly
increased cytoplasmic glucose to ∼9mM. Potentiation of
TOFA and C75 induction of PPAR𝛼 transcription at high
extracellular glucose (20mM) correlated with TOFA and C75
both increasing cytosolic glucose nearly by 2-fold. In an
earlier study, TOFA treatment of rat primary hepatocytes cul-
turedwithKrebs-Henseleitmedium (11mMglucose) induced
glucose accumulation and release into the medium [10]. This
finding was attributed to TOFA inhibiting glycolysis, likely
as a consequence of accelerated fatty acid oxidation, which in
turn decreased the rate of net glucose and glycogen utilization
[10]. Finally, the effects of high glucose in conferring on
fatty acid synthesis inhibitors the ability to induce PPAR𝛼
transcriptional activity were not likely mediated through
glucose-induced posttranslationalmodification of L-FABP or
PPAR𝛼, such as through phosphorylation or sumoylation.
L-FABP does not appear to be modified by these processes
[70, 104, 105]. Although insulin induces phosphorylation of
PPAR𝛼 to activate its transcriptional activity [106, 107], in the
study presented herein insulin was maintained at a constant
level in the culture medium. In addition, high glucose
without inhibitor did not induce PPAR𝛼 transcription of
CPT1A, CPT2, or ACOX1. Likewise, while PPAR𝛼 sumoy-
lation represses PPAR𝛼 activity [108], our studies indicate
that high glucose increased rather than decreased PPAR𝛼
transcriptional activity. It has been shown that hyperglycemic
conditions increase intracellular glucose in a variety of
primary (human endothelial cells, bovine retinal pericytes)
and established (fibroblasts, COS7 cells) cell lines [98, 109].
The studies presented herein demonstrate that high glucose
in the culture medium also increases intracellular glucose in
cultured primary mouse hepatocytes. While it is not known
if hepatic glucose is elevated in diabetes, several studies have
shown that diabetes increased intracellular glucose in muscle
and retinal cells [46, 99].
Sixth, L-FABP contributed significantly to TOFA andC75
induction of PPAR𝛼 transcription in the context of high
glucose in the mouse primary hepatocyte culture medium.
L-FABP provides a signaling pathway for an analogous broad
variety of lipidic ligands (straight and branched chain LCFAs,
LCFA-CoAs, fibrates, and xenobiotics), chaperoning them to
the nucleus [17–20]. L-FABP directly interacts with PPAR𝛼
in the nucleus, and this binding is enhanced at high glucose
(review in [17, 18, 49, 83]). L-FABP gene ablation abolished
the ability of TOFA as well as C75 to stimulate PPAR𝛼
transcription of CPT1, CPT2, and ACOX1 in hepatocytes
cultured with high glucose, apparently by different but
overlapping mechanisms. Thus, our findings indicate that
TOFA and C75 stimulating PPAR𝛼 transcription of LCFA 𝛽-
oxidative enzymes (CPT1A, CPT2, ACOX1) at high glucose
were mediated through L-FABP. Earlier studies from our and
other laboratories showed that glucose binds to both L-FABP
and PPAR𝛼 to alter their conformations and high glucose
increases L-FABP’s binding affinity for PPAR𝛼 [83, 98, 110,
111].
In summary, the fatty acid synthesis pathway has
become a therapeutic target for ameliorating the adverse
effects of obesity as well as its associated type 2 diabetes and
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cardiovascular disease. Drugs such as TOFA and C75 target
the fatty acid metabolic pathway to inhibit synthesis, thereby
decreasing body weight, adipose tissue, hyperlipidemia, and
fatty liver. While initially thought of primarily as inhibitors
of de novo fatty acid synthesis, these agents also exhibit
additional effects in the central sympathetic nervous system
(decrease food intake) and liver (increase CPT1 activity and
fatty acid oxidation) [8–11]. The effects of TOFA and C75
on CPT1A are paradoxical, explained only in part by their
impact on the level of malonyl-CoA and/or direct interac-
tion with the CPT1 enzyme. The results presented herein
demonstrate that TOFA and C75 can also induce PPAR𝛼
transcription.This induction was significantly potentiated by
high glucose in the culture medium and required L-FABP.
L-FABP bound TOFA at classic LCFA binding site(s) on L-
FABP, while TOFyl-CoA and likely C75 and/or C75-CoA
interact through an additional site(s). Within the cell, L-
FABP enhances LCFA uptake, transport through the cytosol,
and provides a signaling pathway for bound ligands into the
nucleus, where L-FABP directly binds to PPAR𝛼 to deliver
the bound ligand (review in [17, 18, 49]). Taken together with
the data presented herein, these findings delineate a novel
mechanism whereby high glucose enables de novo LCFA
synthesis inhibitors to enhance LCFA oxidation through
PPAR𝛼, similarly as demonstrated with natural LCFAs. It
is known that the adverse effects of chronic hyperglycemia
in human subjects are exacerbated by high dietary fat rich
in saturated LCFAs, poor ligands and activators of PPAR𝛼
[19, 20, 24, 112, 113]. In contrast, hypolipidemic drugs such
as fibrates that are more potent PPAR𝛼 agonists appear
more effective in subjects with hyperglycemia such as in
type 2 diabetes than in nondiabetic dyslipidemics [114]. It
is thus interesting to speculate that higher glucose levels in
poorly controlled diabetics may also positively impact fatty
acid synthesis inhibitor activation of PPAR𝛼 transcriptional
activity as compared to the normoglycemic population.
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